Figure 5. (A) Endoscopic polyp score reduction is inversely
correlated with the number of allergen skin prick tests positives
(P=0.023) such that in 100% (5/5) patients with 2 or less positive SPT
benralizumab treatment reduced polyp size. (B) In contrast, 100% (4/4)
of patients with blood eosinophil counts greater than 700/µl improved,
although correlation was not significant (P=0.301). Four-parameter
logistic curves interpolate the correlation inflection points of each
graph.
If we divide the absolute blood eosinophil count by the number of
positive allergen skin prick tests (Eos/SPT), the ratio appears to be a
good predictor of benralizumab induced endoscopic nasal polyp score
reduction (P=0.005). In other words, we found that high baseline
eosinophil count and low number of positive allergen skin prick tests
correlates with better benralizumab induced nasal polyp score reduction
as seen in Figure 6A. Similarly, the ratio of blood eosinophil count to
SPT correlates with benralizumab induced CT scan polyp score reduction,
and this too was statistically significant (P=0.048) as shown in Figure
6B. These preliminary findings in a small group of highly selected
patients may suggest that there is a relationship between allergy skin
testing, blood eosinophil count and benralizumab induced nasal polyp
reduction.